検索結果

千寿製薬株式会社

c suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation channel subfamily V member 1 Inhibition（PDF） 查看新闻 非处方类产品等

千寿製薬株式会社

c suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation channel subfamily V member 1 Inhibition（PDF） News List OTC Products, etc.

Publications | Research & Development | SENJU Pharmaceutica

and carcinogenicity evaluations of motugivatrep (SJP-0132) — a transient receptor potential cation channel subfamily V member 1 antagonist Kotaro Yamada1, Yoshinori Yamagiwa1, Hideya Yonekura1, Satok...

发表论文 | 研究与开发 | 千寿制药株式会社

and carcinogenicity evaluations of motugivatrep (SJP-0132) — a transient receptor potential cation channel subfamily V member 1 antagonist Kotaro Yamada1, Yoshinori Yamagiwa1, Hideya Yonekura1, Satok...

n Japan today. Avarept® represents a novel therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1) *1 antagonist, designed to improve both subjective symptoms and...